AZD 5153 is primarily utilized in the field of oncology research as a potent and selective inhibitor of BRD4, a protein involved in the regulation of gene expression. Its application is focused on studying the role of BRD4 in cancer progression, particularly in cancers that are driven by aberrant gene expression. Researchers use AZD 5153 to explore its potential in disrupting the interaction between BRD4 and chromatin, which can lead to the suppression of oncogenic pathways. This compound is also investigated for its efficacy in combination therapies, where it may enhance the effects of other anticancer agents. Additionally, AZD 5153 serves as a valuable tool in preclinical studies to better understand the mechanisms of bromodomain proteins and their implications in various diseases.